Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

Phase 3 Unknown 120 enrolled Daewon Pharmaceutical Co., Ltd.

RandomizedCrossoverDouble-blindTreatment

Summary

A Multi-center, Randomized, Placebo-controlled, Double-blind, Cross-over, Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients with Primary Dysmenorrhea

Timeline

Start: 2020-09-30
Primary completion: 2021-08-30
Completion: 2021-08-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pelubiprofen	Small molecule	45 mg	—

Phase 3 Clinical Trial to Evaluate of the Efficacy and Safety of DW9801 in Patients With Primary Dysmenorrhea

Summary

Timeline

Drugs

Indications